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Abstract 
 
Osteosarcoma is the most frequent primary tumor of the bone, characterized by an aggressive and 
metastatic potential. Few improvements were achieved in term of therapies in the last two decades. 
Understanding mechanisms underlying chemosensitivity of tumor cells and the discovery of new 
prognostic factors could improve patients’ outcome.  
In this study, expression of CD99 had been evaluated by IHC in 100 OS biopsies, discovering the 
potential of CD99 as a predictive biomarker of ifosfamide response. The importance of CD99 in 
ifosfamide sensitivity was also studied in osteosarcoma cell lines. For the same OS specimens, 
expression of immune infiltrate markers and their correlation with CD99 has been studied. For 
understanding the regulation of CD99 in osteosarcoma, miRNA mediated post-transcriptional 
regulation has been examined. Finally, a small RNA sequencing pilot study has been conducted on 14 
OS samples, with the aim to identify a miRNome able to distinguish at diagnosis patients with high 
probability to relapse. This signature has been validated by qPCR in a larger OS cohort.  
The predictive and prognostic role of CD99 in OS has been reported. In clinical samples, CD99 acts as 
a predictive biomarker for ifosfamide response. CD99 is associated with an increased sensitivity in OS 
cell lines, corresponding to a greater apoptosis rate. CD99 tumoral expression correlates to an 
enrichment in CD8+ and CD68+ cells in OS samples. Taken together these data confirm a role of 
CD99 in ifosfamide sensitivity in osteosarcoma, thus CD99 is able to increase both the cytotoxic and 
the immunomodulatory effects of ifosfamide, making osteosarcoma cells more sensitive. The study 
regarding post-transcriptional regulation of CD99 identifies hsa-miR-330-3p as a modulator of CD99 
expression. Moreover miR-330-3p affects downstream effector of CD99, like ROCK2, leading to a 
modulation of migration capabilities. Finally, a 3 miRNAs signature (hsa-miR-99b-3p, hsa-miR-130b-
5p and hsa-miR-139-5p), identified by small RNA sequencing, discriminates patients who remained 
disease-free from those who relapsed. Enrichment pathways analyses show the involvement of these 
miRNAs in immunological processes and cellular metabolism, underlining the importance of these 
mechanisms in the pathogenesis and response to therapy in OS. 
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1. INTRODUCTION 
1.1 OSTEOSARCOMA 
1.1.1 General aspects 
Osteosarcoma is the most common primary malignancy of bone, despite it is a rare tumor, with a 
worldwide incidence of 4-5 cases per million people per year. In fact, osteosarcoma cases 
represent only 0.2% of all cancers diagnosed (Beckingsale, 2010). 
It has a high social impact because it affects predominantly adolescents and young adults and it 
is characterized by aggressive features like high metastatic potential and incidence of local 
recurrence. There is a minor second peak of incidence in patients older than 60 years. (Savage, 
2011). 
The first peak corresponds to an increased bone growth typical of puberty with a mean age of 
patients of 16 years. The onset in elderly patients is secondary to a previous radiation expositions 
or bone abnormalities, like Paget’s disease (Savage, 2011; Mirabello, 2009) 
Osteosarcoma affects both males and females, with a ratio of 1.6:1; this tumor develops a little 
bit earlier in female rather than in male, reflecting the difference in the beginning of puberty 
existing between the gender. 
In young patients, osteosarcoma occurs mainly in the metaphysis of long bones, such as the 
distal femur, proximal tibia, and proximal humerus: these are bone districts characterized by 
rapid bone growth, corroborating the relationship between osteosarcoma onset and bone 
development during puberty. Anatomic sites change with age, in elderly patients osteosarcoma 
affects flat and axial bones, confirming a different pathogenesis in the two classes of patients 
(Hayden, 2006). 
Osteosarcoma presents a wide range of histological subtypes; the WHO recognize the following 
variants: classic or conventional, small cells, telangiectatic, periosteal and parosteal. All these 
variants have in common an uncontrolled proliferation of mesenchymal-derived cells able to 
produce osteoid matrix (Marina, 2004). 
Classic osteosarcoma represents the most common histological types and it is described as 
formed by cells with different morphology, with pleomorphic and hyperchromatic nuclei. Classic 
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osteosarcoma can be divided in osteoblastic, chondroblastic and fibroblastic, based on the 
predominant type of matrix secreted by tumoral cells (Klein, 2006; Picci, 2014). 
Osteosarcoma is also classified by anatomic location and tumor staging. Most of the cases occurs 
in the intramedullary part of the bone, while only 5% develops on the bone surface.  
Staging system used by Musculoskeletal Tumor Society is the Enneking system and it is based 
on:  
• tumor grade: high grade (I) or low grade (II) 
• tumor extension: intra-compartmental (A) or extra-compartmental (B) 
• presence of distant metastasis (III) 
The staging of a tumor is a measure of the tumor growth and diffusion and considers of its 
microscopic aspect (Picci, 2007). 
1.1.2 Etiology 
The etiology of osteosarcoma is not well understood yet. 
It is possible that factors connected to the growth play an important role in osteosarcoma 
etiology since this tumor mainly occurs during puberty, a period characterized by a rapid 
development and bone remodeling. Many studies confirm an association between taller stature 
and increased risk to develop osteosarcoma, because of a more rapid growth rate during the 
puberty of taller people in respect to the others. Also, high birth weight could be a risk factor for 
this type of tumor.  These association could be explained studying some factors involved in high 
birth weight, such as growth factors and hormones (Reviewed in Mirabello, 2011). 
The IGF system plays a key role in the growth hormone signaling pathways, in addition to its 
function as normal bone growth and development regulator. Also, it was demonstrated that a 
SNP in IGF-IIR gene is associated with an increased risk of osteosarcoma onset (Scotlandi, 
2008).  
There are few knowledges about environmental exposition and osteosarcoma because it is 
difficult to conduct association studies due to the rarity of the tumor and the limited samples size. 
The only validated evidence concerns the exposition to radiation and to beryllium oxide 
(Hayden, 2006). 
Several familiar syndromes predispose to osteosarcoma, such as hereditary retinoblastoma, Li-
Fraumeni syndrome, Rothmund-Thomson syndrome, Werner syndrome and Bloom syndrome. 
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These diseases are extremely rare and due to highly penetrant germline mutations. These 
association studies could provide some important bases for understanding osteosarcoma etiology 
(Kansara, 2007). 
Some authors suggest a viral etiology, based on the evidence that some osteosarcomas show SV-
40 virus sequences. Nevertheless, there are no clinical data supporting that viruses are important 
for the onset of this tumor (Longhi, 2006).  
1.1.3 Genetic and molecular bases of osteosarcoma 
Osteosarcoma is typically aneuploid and lacks specific chromosome translocations, 
characterizing most of sarcomas, like Ewing Sarcoma (Kansara, 2007). 
Osteosarcoma is known for its high genomic instability and complexity of mutations and 
chromosomic rearrangements, proving objects for several genetic and genomics studies with the 
common aim to understand the cause of this catastrophic scenario. 
Several techniques were used for studying mutations and rearrangements at level of both single 
gene and entire chromosome, such as karyotyping, comparative genomic hybridization (CGH), 
fluorescence in situ hybridization, quantitative PCR, single-strand conformation polymorphism 
analysis, genome-wide association studies using single-nucleotide polymorphisms (SNPs). 
Thanks to these studies, it was possible to identify some chromosomic regions that are mainly 
affected by mutations. Numeric abnormalities include gain of chromosome 1 and loss of 
chromosomes 6, 9, 10, 13 and 17; instead, structural rearrangements involve chromosome 11, 19 
and 20 (Kansara, 2007; Hayden, 2006). These common rearrangements could help to better 
comprehend and study genes involved in osteosarcoma development and progression. Thanks to 
these worth cytogenetic studies and genomic analyses, some important genes were identified, 
like RB, mapping on chromosome 13p, and TP53, mapping on 17p (Kansara, 2007; Hayden, 
2006). The importance of these two genes are also supported by the onset of osteosarcoma in 
patients affected by hereditary retinoblastoma and Li-Fraumeni syndrome.  
Oncosuppressor retinoblastoma, Rb, is one of the best characterized gene involved in 
osteosarcoma. It is located on chromosome 13q14 and it encodes for a 110 kDa protein 
belonging to the family of pocket proteins. pRb negatively regulates cell cycle progression from 
G0/G1 to S phase and it is deregulated in all cancers. During G1 phase, pRB binds and 
suppresses E2F1, E2F2 and E2F3 transcription factors. Phosphorylation of Rb by cyclin-
dependent kinases CDK4, CDK6 and CDK2 leads to inactivation of Rb, release of E2F 
transcription factors and subsequently transcription of gene necessary to cell cycle progression, 
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such as cyclin A, D and E. Cyclin-dependent kinase inhibitors (CDKI), p16INK4a and 
p15INK4b, prevent cyclin D and CDK4 functions. In this way they inhibit cell cycle progression 
blocking G1/S transition. 70% of sporadic osteosarcoma cases present Rb mutations, 
homozygous deletions are observed in 23% of cases, instead punctiform mutations in just 6% 
(Kansara, 2007). 
TP53 gene encodes for a transcription factor involved in cell cycle regulation, DNA damage 
response and apoptosis. After a DNA damage, p53 upregulates p21 transcription. p21 binds 
complexes formed by cyclin E/CDK2 or Cyclin D/CDK4/6, resulting in a transient arrest of cell 
cycle. If the damage cannot be repaired, prolonged activation of p53 leads to apoptosis. Germline 
mutations are observed in patients affected by Li-Fraumeni syndrome. These patients are 
predisposed to develop different tumors, included brain, breast, soft tissue, adrenocortical 
tumors, leukemia and osteosarcoma. Osteosarcoma is the second more frequent tumor developed 
in Li-Fraumeni patients, with an incidence of 12%. In sporadic osteosarcoma, TP53 is mutated in 
60% of cases. Different mechanisms may lead to inactivation of p53, such as allelic loss (70-
80%), punctiform mutation (20-30%) and genic rearrangements (10-20%) (Kansara, 2007). 
Murine models of osteosarcoma corroborate the importance of p53 in osteosarcoma 
development. There are different models with a predisposition to osteosarcoma, bringing p53 
mutation or deletion. Instead, Rb mutations alone do not predispose to osteosarcoma 
development in mouse models (Janeway, 2010). 
Furthermore, several aberrations are observed in p53 regulators and effectors, like MDM2 and 
CDKI. 
MDM2, localized on 12q13-q14 chromosome, encodes for a protein able to bind pRB and inhibit 
p53. There is a feedback loop between p53 and MDM2, because p53 controls MDM2 
transcription and MDM2 can block both p53 transcription activity and its transport from the 
cytoplasm to the nucleus. MDM2 also functions as E3 ubiquitin ligase that recognizes the N-
terminal trans-activation domain (TAD) of p53, causing its degradation. MDM2 is amplified in 
17% of osteosarcoma and its expression is associated with the development of local recurrence 
and distal metastasis (Kansara, 2007). 
CDKIs inhibit cell cycle progression and the inactivation of these inhibitors could lead to cell 
transformation and immortalization. INK4A plays a crucial role in the regulation of G1 phase: 
the gene encodes for two different transcripts, p16INK4a and p14ARF. p16INK4a interacts with 
and blocks MDM2: inhibition of MDM2 leads to a stabilization of p53 and subsequently to the 
7 
 
arrest of cell cycle and apoptosis. Homozygous deletion of INK4a is noted in 10% of 
osteosarcoma, correlating with a poor prognosis (Kansara, 2007). 
The complexity of osteosarcoma karyotype could reflect its pathogenesis. This complexity could 
be due to the cycle of chromosomic fusion and break, deriving by telomeric shortening. 
Telomers are nucleoprotein structures that protect chromosomic extremities. Telomeric length is 
one of the check points controlling cell proliferation: when telomers are too short there is an 
activation of a p53-dependent senescence pathway. Tumoral cells bypass this checkpoint through 
keeping the correct telomeric length. About 85% of tumors activate a specific enzyme, called 
telomerase. In the rest of cancers, telomer elongation occurs through a recombination-based 
mechanism named ALT (Alternative Lenghtening of Telomers). About 50% of osteosarcoma 
depends on ALT for the maintenance of telomer functions (Marina, 2004). 
1.1.4 Osteosarcoma and osteoblastic differentiation  
In the last few years osteosarcoma has been considered as a differentiation disease. In fact, 
epigenetic and genetic alterations interrupt the normal bone differentiation. Bone marrow stem 
cells are capable to differentiate into osteoblasts, chondroblasts, adipocytes, muscular cells and 
neural cells. Bone differentiation is an intricate and fine-tuned process influenced by 
environmental and endogenous factors. Several pathways are involved in this process, like WNT, 
BMPs, FGF, IGF. Different stages of osteoblast differentiation are characterized by expression 
of specific marker and progressive loss of proliferating ability (Basu-Roy, 2013). 
Several evidences support the involvement of bone differentiation in osteosarcoma pathogenesis.  
Osteosarcoma is formed by a heterogeneous population of cells, some of which show stem-cell 
like features. Cancer stem cells are characterized by asymmetric division, self-renewal and 
chemoresistance (Wagner, 2011).  Gibbs and colleagues isolated a subpopulation of cell able to 
form spherical colonies, named sarcosphere; these cells express typical stemness markers, like 
Oct3/4, Nanog e STAT3 (Gibbs, 2005). The presence of osteoid matrix suggests that osteoblast 
progenitors may incur in neoplastic transformation (Dani, 2012). In fact, osteosarcoma cells only 
express early marker of bone differentiation like ALP and collagen (Wagner, 2011). 
Loss of differentiation has a prognostic relevance: well-differentiated tumors are classified as 
low grade and have a significantly better prognosis than the undifferentiated ones. Osteoblastic 
differentiation is antagonist to oncogenic process: the last stage of differentiation is the cell-cycle 
exit regulated by the transcription factor Runx2 (Thomas, 2004). 
8 
 
Runx2 belongs to a family of transcription factor characterized by some conserved motifs: a 
DNA binding domain, a protein-protein interaction domain, one with ATPase activity. Runx2 is 
involved in several steps of bone differentiation. Runx2 could be co-activated by Rb; also, 
Runx2 coordinates cell cycle exit through activation of p27KIP1. Both Rb and p27KIP1 are lost 
in osteosarcoma, so Runx2 activity is frequently interrupted in this tumor leading to the loss of 
differentiated phenotype (Thomas, 2004). 
1.1.5 Clinical aspect: from diagnosis to therapy 
Patients affected by osteosarcoma complain pain and swelling. Pain may be prolonged for weeks 
or months, also during the sleep. Swelling appears successively and the interested area becomes 
hard to tact and shows signs of hypervascularity. Often the patients can lose the functionality of 
the limb and frequently it is possible to attend to pathological fractures (Klein, 2006). 
Despite most of the patients show the symptomatology of the primary tumor, some others could 
complain different symptoms like dyspnea, chest pain, hemoptysis and cachexia correlated to the 
metastatic disease.  
The first diagnostic step consists in a X-ray radiography of interested bone showing the osteoid 
matrix and the presence of tumoral mass. Diagnosis is then confirmed by biopsy (Beckingsale, 
2010). 
Even if surgery is a milestone of osteosarcoma treatment, alone it gives only local control of the 
disease. 
The percentage of survival has been improved in the last years, thanks to introduction of 
chemotherapy. The survival rate has increased up to 70% in patients with no metastatic disease. 
Unfortunately, a large fraction of patients show metastases at diagnosis and the survival rate of 
these patients is about 25% (Hayden, 2006). 
Adjuvant therapy consists in surgical removal of tumor and post-operatory chemotherapy. The 
introduction of this kind of treatment for osteosarcoma is one of the biggest success of modern 
cancer treatment (Kansara, 2007). Neoadjuvant therapy was introduced by Rosen in 1978. 
Preoperatory chemotherapy is necessary to reduce tumoral mass and control metastasis. This is 
the last improvement in osteosarcoma cure. 
Doxorubicin and methotrexate were the first two antineoplastic drugs introduced for 
osteosarcoma treatment. Other drugs like vincristine, bleomycin, actinomycin-D were 
immediately abandoned due to insufficient effectiveness. Cisplatin and ifosfamide were added in 
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chemoprotocol many years later (Longhi, 2006). Methotrexate, cisplatin and doxorubicin have 
the highest antitumoral activity in osteosarcoma when used as single agents. Combination of 
these drugs shows synergic effect, leading to a more efficient therapeutic regimen (Beckingsale, 
2010). 
Methotrexate (MTX) is an antagonist of folic acid, which differs from this one for a substitution 
of an amminic group to a hydroxilic group in the pteridine ring. MTX binds catalytic site of 
dihydrofolate reductase (DHFR), interfering with the synthesis of folic acid. Absence of this co-
factor interrupts synthesis of tymidilate, purinic nucleotides, serine and threonine amino acids. 
Thus, MTX inhibits DNA, RNA and protein formation. 
Low dose MTX enters cells by an active transport system via the Reduced Folate Carrier (RFC); 
high dose MTX passively diffuses into the cells. In osteosarcoma, resistance to MTX is mediated 
by DHFR overexpression and RFC downregulation (Guo, 1999). 
Antracyclinic antiobiotics are the most useful antineoplastic drugs ever developed. Doxorubicin 
(DXR) belongs to this class of drugs. The mechanism of action of doxorubicin is complex and 
the drug exerts its toxicity through different pathways. Doxorubicin has high affinity for DNA 
and acts as aspecific intercalating agent, binding and stabilizing ternary complex formed by 
DXR, topoisomerase II and DNA. DXR also binds cellular membrane altering the fluidity and 
ion transport (Chou, 2006). In osteosarcoma, the main resistance mechanism is ABCB1 
overexpression, leading to an active efflux of DXR outside the cell (Serra, 1995). 
Overexpression of ABCB1 is also associated with poor prognosis in this tumor (Serra 2003; 
Serra, 2006). 
Cisplatin was introduced in osteosarcoma treatment in the late 1970s. Cisplatin (CDP) is an 
inorganic metallic compound, able to interact and damage DNA, inducing cell death through 
activation of apoptotic pathway. Cisplatin needs to be activated by aquation: two chloride atoms 
are displaced by two molecules of water. The cytotoxic effects are due to DNA interaction and 
formation of abduct between platin and N7 of purinic bases. Cisplatin induces different kind of 
bonds: between adjacent bases, inter- and intra-strands, DNA-protein. These abducts change 
helix conformation which is recognized by DNA damage repair complexes, like mismatch repair 
complex (MMR). The final effects of cisplatin are cell cycle arrest, inhibition of transcription 
and activation of apoptotic cascade. Similarly to what happens for DXR and MTX, cells display 
different mechanisms of resistance to cisplatin. In osteosarcoma, an increased activity of 
glutathione and glutathione S-transferase (GSH/GST) detoxification system is responsible for 
CDP resistance (Siddik, 2003). 
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Thanks to the introduction of MAP (combination of MTX, DXR and CDDP) therapy, overall 
survival of patients with localized disease were risen to 65%.  
Other two drugs can be used in combination with MAP therapy: ifosfamide and etoposide. 
Ifosfamide was introduced in osteosarcoma therapy in the ‘80s. Ifosfamide is an alkylating agent 
belonging to the class of oxazaphosphorine. It is administered as a prodrug and it undergoes to 
liver activation by cytochrome P450. The metabolism produces several active compounds, like 
nitrogen mustard, 4-hydroxyifosfamide and acrolein. (Giraud, 2010). The cytotoxic effect 
depends on the DNA crosslink through formation of covalent bonds. Little is known about the 
specific mechanism of action of oxazaphosphorines. Ifosfamide and its active compounds are 
hydrophilic and their transport inside the cell is mediated by active transporters like breast cancer 
resistance protein (BCRP), some members of multidrug resistance protein (MRP1, MRP2, 
MRP4), organic anion transporter (OAT) and organic cation transporter (OCT). Resistance to 
ifosfamide is due to active efflux thanks to upregulation of the transporters; an increased 
detoxification of oxazaphosphorines metabolites through aldehyde dehydrogenase (ALDH), 
glucose-6-phospate dehydrogenase (G6PD), GSH and GST system; anti-apoptotic response to 
cellular damages and increased repair of DNA (Zhang, 2005). Nothing is known about the exact 
mechanism of resistance in osteosarcoma. 
Etoposide is often coupled with ifosfamide in sarcoma treatment; etoposide alone shows a low 
cytotoxic effect in OS cells. This drug is a podophyllotoxin that interacts with topoisomerase II, 
forming a complex DNA-enzyme (Gill, 2013).  
Unfortunately, no progress has been made in the therapy regimens over the last 30 years. 
Probably a better comprehension of molecular pathogenesis of OS could identify important 
deregulated pathways, giving the possibility to develop new targeted therapies. 
Only one new drug is approved for treatment of localized disease: MTP-PE. MTP-PE is a 
synthetic lipophilic analogue of muramil dipeptide; it is able to selectively activate macrophages 
and monocytes and induces secretion of some cytokines, such as IL-6 and TNF-α. Clinical 
studies show that introduction of MTP-PE decreases local relapse rates and improves survival 
rate up to 78% (Meyers, 2008). 
1.1.6 Prognostic factor 
In the last years, a large number of studies have been conducted with a common aim: identify 
novel biomarkers. Prognostic and predictive biomarkers are useful tools for improving cancer 
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treatment. Unfortunately, there are discordant opinions about the value of some factor identified, 
probably due to lack of uniformity in techniques used and cohort selection. 
Age at diagnosis, anatomic location and histological subtypes, volume of tumor, low 
chemoresponsiveness, type of surgery and chemoprotocol are clinical factors often associated 
with a worse prognosis (Longhi, 2006). 
Thanks to neoadjuvant chemotherapy, it is possible to measure the tumor responsiveness to 
chemotherapy, evaluating necrosis grade of the tumor after surgical removal. Tumoral necrosis is 
a widely-accepted prognostic factor. A high percentage of necrotic cells significantly correlates 
with a better prognosis, both in term of event-free survival and overall survival (Gill, 2013). 
Several biological factors are considered in multiple studies and show antithetical value. 
High level of alkaline phosphatase and lactate dehydrogenase seem to correlate with worse 
prognosis (Bacci, 2006).  
P-glycoprotein (ABCB1) is the only biological factor recognized for its prognostic relevance. 
Several studies show that the overexpression of this ATP-dependent pump is a negative 
prognostic factor in osteosarcoma patients. Based on expression level of ABCB1, patients are 
stratified before the beginning of pre-operatory chemotherapy and follow different schedule of 
drugs administration (Scotlandi, 1996; Serra, 2003). 
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1.2 The molecule CD99 
1.2.1 General aspects 
CD99 was described as an antigen recognized by 12E7 monoclonal antibody for the first time in 
1979 by Levy and colleagues. They demonstrated that CD99 is highly expressed in cortical 
thymocytes and acute lymphoblastic leukemia (ALL), but absent in medullary thymocytes and in 
chronic myeloid leukemia (CML) and chronic lymphatic leukemia (CLL) (Levy, 1979). This 
protein is codified by MIC2 gene, the first pseudoautosomal gene ever identified (Goodfellow, 
1980, Goodfellow, 1983; Goodfellow, 1986; Smith, 1993). MIC2 is 50 kbp long and it is 
composed by ten exons; it is oriented toward the centromers and maps in the pseudoautosomal 
region of sexual chromosomes (Xp22.3- Xpter and Yp11-Ypter). MIC2X and MIC2Y genes are 
strictly correlated to each other and their products are biochemically equal. Moreover, MIC2X is 
not subjected to chromosome X inactivation, maintaining the same genic dosage in males and 
females (Goodfellow, 1984). Product of MIC2 gene does not show any homology with known 
proteins except for Xg, an erythrocyte antigen. The homology covers the 48% of the amino acid 
sequences, probably due to a duplication of an ancestral gene resulting in the formation of these 
two genes (Fouchet, 2000). CD99 is a glycoprotein, localized into cell membranes, with a 
molecular weight of 32 kDa. CD99 has one extracellular domain of 100 amino acids highly O-
glycosilated, a hydrophobic transmembranous domain of 23 residues and a C-terminal 
intracellular portion of 38 amino acids. The intracytoplasmatic domain has a hairpin structure 
bond to the membrane by two flexible handles; a consensus site for PKC is present in this 
domain, that includes a serine residue in position 168 (Alberti, 2002; Kim, 2004). 
1.2.2 CD99 and physiological role 
CD99 has a ubiquitous expression in normal cells and tissues. Immunohistochemistry analyses of 
several human tissues report a high expression in: cortical thymocytes, a subgroup of 
lymphocytes presents both in bone marrow and lymph nodes; endothelial cells of blood vessels; 
Langerhans cells in pancreas; testis cells such as Sertoli and Leidig cells; ovary granulosa cells 
and ependymal cells of brain and spinal canal (Ambros, 1991). 
CD99 is expressed in all leukocyte cell types in thymus, bone marrow and peripheral blood and 
its expression is inversely correlated to differentiative stage in lymphatic and granulocytes 
lineage (Dworzac, 1994). Moreover, CD99 is expressed at high level in B- and T- memory cells 
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(Park, 1999). Recently, a colocalization CD99-MHC I/II has been demonstrated in 
immunological synapsis, suggesting an involvement of CD99 in immune response (Pata, 2011). 
Natural ligand of CD99 is still unknown, the use of monoclonal antibodies (mAbs) is necessary 
for studying downstream effectors. The binding CD99-mAb activates the signal cascade. CD99 
is involved in adhesion and apoptosis of T cells: activation through mAbs interferes with the 
rosette formation and induces externalization of phosphatidyl-serine in thymocytes but not in 
mature T cells (Aussel, 1993). Moreover, triggering of CD99 induces homotypic aggregation and 
apoptosis in Jurkat cells and in CD4+ CD8+ cortical thymocytes, but not in medullary 
thymocytes or other T cells (Bernard, 1995; Bernard, 1997). The apoptotic process is Fas/CD95 
independent and it is not characterized by DNA fragmentation (Bernard, 1997). Homotypic 
aggregation induced by CD99 in T cells does not activate LFA-1/ICAM-1 signaling pathway and 
it is strictly associated to actin remodeling and it depends on Ca2+ release and ERK activation 
(Kasinrerk, 2000; Hanh, 2000). Furthermore, activation of CD99 induces aggregation in B cell 
through a LFA-1/ICAM-1 dependent mechanism (Hanh, 1997). CD99 acts as a co-stimulator of 
T-cells activation in peripheral blood, favoring proliferation and expression of typical markers of 
activated T cell (Waclavicek, 1998; Wingett, 1999). CD99 influences the maturation process in 
thymocytes facilitating the interaction between TCR and MHC complexes through modulation of 
intracellular trafficking. Stimulation of CD99 induces the transport of TCR and MHC to 
plasmatic membrane, resulting in a higher expression of these proteins at cellular junctions. This 
process leads to a positive selection of thymocytes, because cells able to recognize complex 
MHC/Antigen are driven to proliferation, maturation and migration (Choi, 1998). Yoon and 
colleagues confirmed the role of CD99 in cellular trafficking, demonstrating that CD99 
activation in Jurkat cells induces transport of some proteins (TCR, LFA-1, ICAM-1, CD5 and 
GM1) to plasma membrane through the remodeling of actin cytoskeleton (Yoon, 2003). So, 
CD99 may have a physiological role in maturation and activation of T cells. 
CD99 is also involved in the process of transendothelial migration. The interaction between 
CD99 molecules on the surface of endothelial cells and of monocytes is fundamental for the 
diapedesis (Shenkel, 2002; Lou, 2007). Furthermore, CD99 is an important factor of inverse 
transmigration, a process similar to diapedesis, through which activated dendritic cells migrates 
from inflammatory sites to lymph nodes (Torzicky, 2012). 
1.2.3 CD99 and cancer 
CD99 is expressed in a wide range of cancers and its role depends on the cellular context. In fact, 
CD99 may act as oncogene or a tumor suppressor gene.  
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In hematological malignancies an oncogenic role of CD99 is described in T-cell of acute 
lymphoblastic leukemia (T-ALL), where its expression correlates with minimal residual disease 
(Levy, 1979; Dworzac, 2004). Antigen CD99 is expressed in cells of lymphoblastic lymphoma 
and anaplastic large cells lymphoma (Sung, 2005; Buxton, 2009). In diffuse large B cell 
lymphoma CD99 is associated to an advanced stage of the disease and correlates with 
unfavorable prognostic factors (Lee, 2011). Dworzac and colleagues demonstrated that 
expression pattern of CD99 is maintained despite the neoplastic transformation in B cell 
lymphoblastic leukemia (Dworzac, 1999). Also, CD99 is expressed in solid tumors, such as 
embryonal rhabdomyosarcoma (Kovar, 1990; Ambros, 1991; Ramani, 1993), synovial sarcoma 
(Fisher, 1998), mesenchymal chondrosarcoma (Granter, 1996) and ovaric carcinoma (Cho, 
2006). CD99 positively correlates with more malignant characteristics in melanoma (Wilkerson, 
2006). In breast cancer, CD99 is highly expressed but it has no prognostic relevance (Wilkerson, 
2006; King, 2007).  Gastrointestinal and pulmonary neuroendocrinal tumors show a 
heterogeneous expression of CD99 and the percentage of positive cells significantly correlates 
with tumor invasion and metastasis formation (Pelosi, 2000).  CD99 is expressed at high level in 
tumors of central nervous system and brain, like ependymoma, astrocytomas and glyomas 
(Mahfouz, 2008; Ishizawa, 2008; Seol, 2012). CD99 seems to be involved in cellular migration 
in astrocytomas and its expression is increased in more malignant tumors (Urias, 2014). Among 
several cancers expressing CD99, Ewing sarcoma (ES) and neuroectodermic primary tumors 
show the highest level of CD99, which is considered as a diagnostic marker for these diseases 
(Kovar, 1990; Ambros, 1991). CD99 has an oncogenic role in ES and its expression promotes 
proliferation and migration (Kreppel, 2006). Silencing of CD99 reduces tumorigenic and 
metastatic abilities in vitro and in vivo. Also, loss of CD99 leads to neural differentiation through 
expression of differentiative markers, such as H-NF and β3-tubulin, and neurites formation 
(Rocchi, 2010). In Ewing Family Tumors (EFT), the treatment with blocking mAbs direct to 
CD99 induces homotypic aggregation and great rate of apoptosis, reduces anchorage-
independent growth and tumorigenesis in vivo. Downstream effects include cytoskeleton 
remodeling and do not involve protein kinases pathways (Sohn, 1998; Scotlandi, 2000; Cerisano, 
2004). Combined treatment of mAbs and doxorubicin or vincristine shows addictive effect 
(Guerzoni, 2015). 
On the other hand, several tumors show a low expression of CD99, suggesting an 
oncosuppressive role of this antigen. In gastric adenocarcinoma, loss of CD99 is associated to 
de-differentiation of neoplastic cells (Jung, 2002). Also, in pancreatic neuroendocrinal tumor, 
high expression of CD99 is associated to a better outcome (Maitra, 2003; Goto, 2004). Recent 
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studies have been demonstrated the oncosuppressive role of CD99 in multiple myeloma: CD99 
level positively correlates with prognosis (Shin, 2014). In Hodgkin lymphoma, CD99 is not 
expressed unlike in normal B immature cells. Loss of CD99 is crucial for the formation of large 
tumoral cells typical of this neoplasia (Kim, 1998; Kim, 2000). CD99 acts in osteosarcoma as an 
oncosuppressor gene. CD99 is expressed in normal osteoblast and not in OS cells (Barteaux, 
2005). CD99 expression favorites ECM adhesion, inhibits migration and anchorage-independent 
growth in vitro, reduces tumorigenic and metastatic potential in vivo. Ectopic expression of 
CD99 induces the formation of a complex with caveolin-1 and c-Src, leading to a decreased 
activity of the kinase (Manara, 2006; Scotlandi, 2007). Also, forced expression of CD99 in OS 
cells stimulates the recruitment of N-cadherin and β-catenin to cellular junctions and induces 
cytoskeleton remodeling. Moreover, CD99 inhibits ROCK2 signaling, crucial for OS cell 
migration (Zucchini, 2014). 
  
16 
 
1.3 microRNA  
1.3.1 General aspects 
miRNAs belong to the class of non-coding RNA. They are 19-25 nucleotides long, so they are 
defined as small non-coding RNAs. miRNAs regulate gene expression through the interaction 
between their seed sequence and mRNA target. Usually the pairing is not perfect and occurs in 
the 3’UTR of mRNA target. Binding of miRNA to its target induces translation repression and 
mRNA degradation. There is some exception to canonical mechanism of action of miRNAs: the 
binding may involve the 5’UTR or other region of mRNA target; pairing could be perfect; it’s 
possible to assist to target up-regulation. miRNAs belong to the most abundant class of 
transcriptional regulatory molecules, involved both in physiological and pathological processes 
(Di Leva, 2014). The first miRNA was described in 1993 when two independent studies in C. 
elegans demonstrated that heterochronic gene lin4 does not codify for a protein but for 2 small 
RNA, one 22 nucleotides long and its precursor of 61 nucleotides. These studies also showed a 
complementarity between lin4 and the 3’UTR of lin14. These small RNAs were considered a 
proper method in nematodes for regulating larval development and were named small temporal 
RNA (stRNA). In 2001, RNAs with similar features were described in other organisms. Then, a 
big class of small-RNA with regulatory activity were universally recognized as microRNAs (Di 
Leva, 2006). 
1.3.2 miRNAs biogenesis and mechanism of action 
miRNAs biogenesis starts from the transcription of pri-miRNA operated by RNA pol II. Like all 
Pol II transcripts, pri-miRNAs have a 7-methyl-guanosine cap at 5’ extremity and a poli(A) tail 
at 3’. Genes encoding for miRNA have different location into the genome: in intergenic regions, 
in the antisense strand in respect to the near gene, in intronic regions. For the first two cases, it is 
frequent to find cluster of pri-miRNA and the transcript usually is polycistronic. When the 
miRNA is located into an intron, its expression is associated to the expression of the gene. pri-
miRNAs have the same hairpin secondary structure, independently by genome location, with 
exception for miRNA located in intronic sequences. 
The hairpin is processed by a proteic complex, called the microprocessor, formed by the 
endonuclease Drosha and its cofactor DGCR8. Drosha makes an asymmetric cut on both strands 
of the hairpin structure near the terminal loop. The product is a pre-miRNA presenting a 5’ 
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phosphorilated and a 3’ hydroxylated with an overhang of 2 nucleotides. DGCR8 discriminates 
the substrate thanks to its two dsRNA binding domains (Gregory, 2005).  
An alternative biogenesis mechanism is Drosha-independent and concerns to miRtrons, the 
miRNA located into intron of a coding mRNA; their processing is operated by the splicing 
machinery.  
pre-miRNAs are transported into the cytoplasm by Exportin5 (Exp5/RanGTP). Exp5 forms a 
complex with RanGTP and the pre-miRNA. This interaction depends on miRNA structure and it 
is not influenced by pre-miRNA sequence. The complex Exp5/RanGTP/pre-miRNA reaches the 
cytoplasm through nuclear pores. GTP hydrolysis mediates pre-miRNA release. The pre-miRNA 
is processed into a 18-33 nucleotides duplex by another RNase III, Dicer-1, and its cofactor, 
TRBP. Dicer-1 is highly conserved among the species and is formed by several domains: one for 
dsRNA binding; one responsible of 3’ extremity binding of small RNA, called PAZ; other 
domains with ATPase and helicase activities. PAZ domain interacts with 3’ overhang and the 
dsRNA binding domain with the duplex. pre-miRNAs are correctly placed into Dicer thanks to 
the presence of the loop and its dimension. Dicer cuts the pre-miRNA, forming a RNA duplex of 
21 bp. ds-miRNA are characterized by a phosphorylation at 5’ extremity and a 2 nucleotides 
overhang at the 3’. (Di Leva, 2006; Meister and Tuschl, 2004). 
ds-miRNAs are incorporated into miRISC complex, which is responsible of miRNAs activities. 
The catalytic core of the complex is formed by Ago proteins. Argonaute family proteins are quite 
similar to RNase H, with a PAZ domain and a PIWI domain, and nuclease activity responsible of 
target cleavage. After the bond with the complex, the two strands are unwound thanks to the 
helicase activity of miRISC. One strand remains associated to the complex, this is the mature 
miRNA. The other strand, called passenger strand, is degraded. The choice of which strand is 
incorporated depends on thermodynamic instability and weaker base pairing at the 5’ end 
relative to the other strand (Di Leva, 2006). Mature miRNA is now able to regulate gene 
expression at post transcriptional level. Interaction miRNA-mRNA occurs at the 5’ end of 
miRNA where the seed sequence is located and a complementary site usually sited in the 3’ UTR 
of the mRNA target. Seed sequence is essential both for target selection and regulation. When 
the complementarity between miRNA seed sequence and mRNA target is perfect, miRISC 
cleaves the target. Imperfect pairing leads to a translation block at ribosomal level. It may 
happen that miRISC complexed to the target is carried into P-bodies, which are cytoplasmatic 
foci with storage function (Lynam-Lennon, 2009). Other regulation mechanisms consist in 
destabilization of mRNA target by de-capping or de-adenylating (Filipowicz, 2008). miRNAs 
regulate several physiological functions, such as proliferation, differentiation, apoptosis and 
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stress response. However, the function of a miRNA depends on mRNA target. A single miRNA 
may target multiple genes and vice versa, one mRNA may be regulated by more than one 
miRNA. 
1.3.3 miRNA and cancer 
A study conducted in Croce’s lab revealed the involvement of miRNAs in cancer. In particular, 
miR-15a and miR-16-1 are codified by a region frequently deleted in chronic myeloid leukemia 
(CML). These two miRNAs act as oncosuppessor and loss of that genomic portion may be the 
initial event for leukemogenesis in CML (Croce, 2009). After this observation, the same group 
began to map all the known genes encoding for miRNA. These genes are usually located in 
chromosomic region which undergo in rearrangements in several tumors. They suggested that 
miRNAs can act both as oncogene and oncosuppressor. Chromosomic regions containing 
oncosuppressive miRNA are located in fragile sites where deletions and mutations occurs more 
frequently. miRNAs with oncogenic features map in region prone to amplification. These 
evidences highlight that miRNAs expression alterations have a key role in neoplastic 
transformation (Calin, 2003). 
Several mechanisms control miRNAs expression and they are aberrantly modulated in cancer. 
The first mechanism studied were chromosomic rearrangement. Then, miRNA genes may be 
interested by sequence variations, like SNP. If a SNP occurs in the seed sequence, the spectrum 
of target genes changes, favoriting oncogenesis. However, no tumor-specific mutations have 
been reported yet (Iorio, 2012).  Like genes encoding for protein, miRNA genes may be involved 
in epigenetic change. miRNA loci are associated to CpG islands, thus changes in DNA 
methylation are recorded. Genes of oncosuppressive miRNA present hypermethylated promoter 
region, instead oncomiR genes are hypomethylated. Also, histone acetylation represents an 
epigenetic mechanism which is deregulated in cancer. Reduction in histone acetylation decreases 
anti-oncogenic miRNA expression.  
However, miRNAs regulate expression of components of the epigenetic machinery, resulting in 
an intricated scenario of feedback regulation. Deregulation of miRNA expression could reflect 
an altered transcriptional activity.  Also, miRNAs could be modulated as result of defect in their 
biogenesis. Dicer and Drosha have oncosuppressive features and their silencing induces 
tumorigenesis in vivo. Alteration on miRNA target genes have been observed such as variants on 
target sequences and secondary structures formation. These secondary structures can impair the 
formation of miRNA-mRNA annealing. By this mechanism the regulation of miRNAs towards 
their targets is hampered (Iorio, 2012). 
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Usually, miRNAs are repressed in tumoral tissue respect to the normal counterpart, indicating a 
general loss of differentiation. miRNA deregulation is associated to neoplastic transformation. 
Indeed, miRNAs influences all six hallmarks of malignant cells: a) sustain proliferative signaling 
(let-7 family); b) evasion growth suppressors (miR-17/19 cluster); c) resistance to apoptosis 
(miR-34a); d) infinitive replicative potential (miR-372/373 cluster); e) angiogenesis (miR-210); 
f) invasion and metastasis (miR-10b) (Di Leva, 2014). 
miRNA expression is strictly tissue- or cellular-specific, so each miRNA could act as oncomiR 
or oncosuppressor miRNA, depending on the cellular context. 
1.3.4 miRNA as biomarkers 
miRNA expression profiling studies are based on alteration of miRNA in tumoral tissue respect 
normal ones. Several techniques have been developed for evaluating miRNA expression. Most 
used are Microarray and Next Generation Sequencing, qPCR and in-situ hybridization, 
depending on the aim of the study (expression of all miRNAs or one specific miRNA). First 
studies of miRNAs profiling highlighted how these profiles could classify different tumoral 
types. Lots of studies demonstrated how several groups of miRNAs are mainly deregulated in 
specific tumors and other are associated to diagnosis, staging, progression, prognosis and 
chemotherapy response (Iorio, 2011; Di Leva, 2013). Cancer shows a specific miRNA signature, 
called miRNome or miRNA fingerprinting, which characterizes malignant state and defines 
some clinic-pathological features. miRNA may have prognostic and therapeutic potential and an 
important role in tumorigenesis (Di Leva, 2014).  
Biomarkers are biological indicators of pathological state and they are useful tool for defining 
tumoral subtypes or evaluating therapy efficacy. miRNAs could be perfect biomarkers in clinical 
practice thanks to: their stability in formalin fixed samples, relative ease quantification, potential 
in discriminating pathological state and association with clinico-pathological characteristics 
(Hauptam, 2013). Discovery that miRNAs are present in biological fluid, such as serum, saliva, 
urine, blood and breast milk, leads to an increased number of studies for identifying miRNA as 
non-invasive biomarkers predictive of both disease progression and therapeutic responses (Shen, 
2013). 
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2. AIM OF THE PROJECT 
 
Osteosarcoma is the most frequent primary tumor of the bone, characterized by an aggressive 
and metastatic potential. Few improvements were achieved in term of therapies in the last two 
decades. Understanding mechanisms underlying chemosensitivity of tumor cells and the 
discovery of new prognostic factors could improve patients’ outcome. On the other hand, a 
relationship between tumor and immune system has been extensively demonstrated. The 
interplay between tumors and their immunologic microenvironment is complex and difficult to 
understand, but a greater comprehension of this interconnection is important for the development 
of novel prognostic markers and improve therapeutic strategies. Only sporadic and controversial 
information are available for the immune cells infiltrating osteosarcoma. It has been 
demonstrated that CD99 shows oncosuppressive features in osteosarcoma. In fact, it’s expressed 
at low level, induces cell adhesion to ECM and inhibits migratory and anchorage-independent 
growth abilities in vitro, while in vivo suppresses tumorigenic and metastatic potential. 
Furthermore, this protein plays a key role in modulating several functions of immune cells, such 
as proliferation and activation of lymphocytes, regulation of MHC class I molecule transport, T-
cell migration and diapedesis of monocytes across endothelium. In this study, expression of 
CD99 has been evaluated by IHC in 100 osteosarcoma biopsies, discovering the potential of 
CD99 as a predictive biomarker of ifosfamide response. The importance of CD99 in ifosfamide 
sensitivity has been studied in osteosarcoma cell lines. For the same tumor specimens, 
expression of immune infiltration markers and their correlation with CD99 has been considered. 
For understanding the regulation of CD99 in osteosarcoma, miRNA mediated post-
transcriptional regulation has been examined. Prognostic relevance of miRNAs emerged in the 
last years. Thanks to tissue- and cell- specificity, it is possible to identify a miRNA signature 
able to discriminate patients with better prognosis. A small RNA sequencing pilot study has been 
conducted on 14 OS samples, with the aim to identify a miRNome able to distinguish at 
diagnosis patients with high probability to relapse. This signature has been validated by qPCR in 
a larger OS cohort. 
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3. MATHERIALS AND 
METHODS 
 
Immunohistochemistry 
Osteosarcoma specimens were incorporated in tissue microarrays (TMA). Two or three 
representative areas (1 mm in diameter) of each tumor were selected for TMA production by first 
examining hematoxylin and eosin-stained osteosarcoma biopsies slides and then sampling tissue 
from the corresponding paraffin blocks. A tissue microarray instrument (Beecher Instruments 
Inc, Sun Prairie, WI, USA) was used for TMA assembly. From TMA blocks, 3-μm-thick 
sections were immunostained using mouse anti-CD99. Percentage of positive cells and 
cytoplasmic staining intensity were scored in semiquantitative manner. Data of immunostaining 
for CD3, CD8, CD20, CD68, PD-1, PDL-1, FOXP3 were already available. 
Cell lines 
Cell lines U-2 OS, SaOS-2 and HEK293 were obtained from American Type Colture Collection 
(Rockville, MD, USA); IOR/OS9, IOR/OS10, IOR/OS15, SARG, OS-PDX#1-C4, OS-PDX#19-
C2 were stabilized and characterized at CRS Development of Molecular Therapies, Laboratory 
of Experimental Oncology, Rizzoli Orthopaedic Institute (Bologna, IT). U-2 OS stably 
transfected for overexpression of CD99 were previously described in Manara et al (Manara, 
2006). Each cell line has been tested for mycoplasma contamination (MycoAlert™ mycoplasma 
detection kit, Lonza, Verviers, Belgium) and authenticated by STR PCR analysis. Cells were 
cultured in IMDM (Lonza), supplemented with 100 units/ml penicillin, 100 μg/ml streptomycin 
and 10% inactivated fetal bovine serum (FBS) (Lonza). 
MTT assay 
To assess drug sensitivity, MTT assay (Trevigen Inc, Gaithersburg, MD, USA) was used 
according to manufacturer’s instructions. Cells were plated into 96 well-plates (2500 cells/well). 
After 24 hours, various concentrations of doxorubicin (DXR 0.3 -1000 ng/ml) (Pfizer, New York 
City, NY, USA), methotrexate (MTX 1 - 300 nM) (Teva Italia srl, Milano, IT), cisplatin (CDP 
0.3 – 3 μg/ml) (Teva Italia srl), 4-hydroperoxyifosfamide (4-HOO IFO 0.3 - 100 μM) (Niomech 
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– IIT GmbH, Bielefield, Germany) were added and cells exposed to these drugs for up to 96 
hours.  
 
Flow cytometry analysis 
The expression of ABC transporters was analyzed by indirect immunofluorescence and flow 
cytometry analysis (FACS Calibur, Becton Dickinson, Milan, IT). Cells were fixed in 4% PFA 
and washed with PBS-BSA1%-Tween20 0.5% (PAT) and permeabilized with 0.15% Triton X in 
PBS. Then they have been resuspended in anti-MRP1 1:20 + Goat anti-mouse IgG (H +L) FITC 
1:100 (Thermo Fisher Scientific Inc, Waltham, MA, USA); anti-MRP4 1:20 + Goat anti-rat IgG 
(H +L) FITC 1:40 (KPL); anti-ABCG2 1:20 + Goat anti-mouse IgG (H +L) FITC 1:100 
(Thermo Fisher Scientific Inc). 
For cell cycle analysis, cell cultures were incubated with 10 μM bromodeoxyuridine (BrdUrd) 
(Sigma-Aldrich, Milan, IT) for 1 h in CO2 atmosphere at 37°C. Harvested cells were fixed in 
70% ethanol for 30 min. After DNA denaturation with 2 N HCl for 30 min at room temperature, 
cells were washed with 0.1 M Na2B4O7, pH 8.5, processed for indirect immunofluorescence 
staining, using α-BrdUrd (Becton Dickinson) diluted 1:4 as a primary MAb, stained with 20 
μg/ml propidium iodide and analyzed by flow cytometry (FACSCalibur; Becton Dickinson).  
RNA extraction and Real-Time PCR 
Total RNA from tumor samples was isolated from snap-frozen tissue material using Trizol LS 
Reagent (Thermo Fisher Scientific Inc). To check whether extracted RNA was representative of 
OS cells, the tissue was morphologically analyzed after hematoxylin–eosin staining. Oligo dT 
primers (Thermo Fisher Scientific Inc) were used to reverse transcribe RNA with a 260/280 nm 
absorbance ratio of 1.5-2. Quantitative Real-Time PCR was performed on ABI Prism 7900 
(Thermo Fisher Scientific Inc). Expression of several genes belonging to immunological 
pathway were performed through TaqMan™ Array Human Immune Panel. Expression levels of 
target genes were normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
CD99 expression was performed using Predesigned TaqMan probes (Hs00908458_m1) (Thermo 
Fisher Scientific); expression data were normalized to GAPDH levels.  
qRT-PCR analysis of miRNAs has been carried out using TaqMan® MicroRNA Assays and 
TaqMan® Universal PCR Master Mix, no AmpErase® UNG (Thermo Fisher Scientific) 
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according to manufacturer's instructions. RNU6b was used as reference gene for expression data 
normalization. 
The relative quantification analysis was performed on the basis of the 2-ΔCT method, in order to 
compare two samples groups (NED vs REL). 
miRNA-mRNA target prediction.  
miRNA target prediction of CD99-3’UTR was performed through the webtool MirWalk v.2 [6], 
considering targets predicted with a consensus of at least 6 tools. 
Luciferase assay 
To generate CD99 luciferase reporter constructs, the 3′UTR of the gene was cloned downstream 
of the luciferase-coding sequence in the psiCHECK-2 at the XhoI and NotI restriction sites 
(Promega, Madison, WI, USA). Mutations were introduced into the miRNA-binding sites by 
using the QuikChange Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA). All the 
transfection studies were performed with 500 ng of each plasmid and 100nM of pre-miRNA. 
Luminescence signal were detected through GloMax Multi Detection system (Promega) 
according to manufacturer’s instructions. 
Western blotting 
Cell lysis was performed on ice with UPSTATE buffer for phosphorilated proteins (50mM Tris-
HCl pH 7.4, 150mM NaCl, 1% NP-40, 1mM EDTA, 0.25% sodium deoxycholate, 1mM NaF) 
upon addition of proteases inhibitors (1:100): aprotinin (10μg/ml), leupeptin (0.1mM), PMSF 
(1mM), sodium orthovanadate (0.2mM). After 30 minutes incubation, lysates were centrifuged 
and proteins from solution fraction were collected. Protein concentration was calculated upon 
dilution in Protein Assay (Bio-Rad) (1μl in 999μl) and spectrophotometer reading compared to a 
standard curve. Equivalent amounts of total cell lysates were separated by 10% SDS-PAGE 
under denaturating conditions and transferred onto nitrocellulose membrane (Bio-Rad 
Laboratories, Milan, IT). Red Ponceau S (Sigma-Aldrich) staining was used to evaluate transfer 
quality. Membranes were blocked for 1 hour at room temperature with milk diluted in TBST (10 
mM Tris-HCl pH 7.4, 150 mM NaCl e 0.1% Tween20) and then incubated overnight with the 
following primary antibodies: anti-actin, anti-CD99, anti-ROCK2. Membranes were then 
incubated with secondary anti-rabbit or anti-mouse antibodies conjugated to horseradish 
peroxidase (GE Healthcare, Little Chalfont, UK) and revealed by ECL Western blotting 
detection reagents (GE Healthcare). 
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In Vitro Migration Scratch.  
U-2 OS osteosarcoma cells were transfected with antagomiR-330 (Thermo Fisher Scientific Inc). 
Twenty-four hours after transfection, a cell-scratch spatula was used to make a scratch in the cell 
monolayer, after which the cell monolayers were rinsed and further incubated. Pictures of the 
scratches were taken by using a digital camera system coupled to a microscope (Nikon 90i 
Eclipse) (Nikon Corporation, Tokyo, Japan) 
Statistics 
Differences among means where analyzed using two-sided Student’s t test (Graphpad Prism). 
IC50 values were determined using CalcuSyn software (Biosoft). Correlations analysis were 
performed using Spearman correlation test. Kaplan-Meier proportional risk log rank test was 
applied for survival curves. Event-free survival (EFS) and overall survival (OVS) were 
considered individually from the date of diagnosis to the date of event. Univariate predictors of 
outcome were entered a Cox proportional hazard model using stepwise selection to identify 
independent predictors of prognosis, considering the 95% CI (IBM SPSS). 
Small RNA sequencing 
21 samples were submitted for small RNA sequencing through Illumina Platform. Integrity of 
RNA was evaluated by 2100 Bioanalyzer (Agilent Technologies) and samples with RIN > 7 
were analyzed. Library preparation and sequencing were performed according to manufacturer’s 
instruction (Illumina, San Diego, CA, USA) 
sRNAseq Analysis 
sRNAseq sample files were firstly trimmed of Illumina standard 3’ adaptor sequences via the 
tool Cutadapt. Trimmed samples were then analysed for miRNA profiling leveraging on 
miRBase version 20 annotation database and by employing the pipeline miARma-Seq, which 
included the tools: Bowtie v1 to align trimmed reads against the human genome (GRCh37), 
featureCounts for read count summarizing, and the Bioconductor package EdgeR for differential 
expression analysis. As recommended, reads were normalized using the TMM method (trimmed 
mean of M-values) and the exact tests to calculate differences between two groups of negative-
binomial counts was performed to gather the log2 fold change, as well as the Benjamini and 
Hochberg false discovery rate (FDR) for each miRNA. Subsequently, expressed miRNAs were 
retained if their average expression counts were >100 in at least one condition. From these, those 
with an absolute log2 fold change (log2FC) value >1 were selected for subsequent analyses. 
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Gene expression Analysis 
Gene expression profile was performed by GeneChip® Human Transcriptome Array 2.0 (HTA 
2.0 - Affymetrix) for the same 21 samples used for smallRNA seq experiment. Gene level 
normalization was carried out by the Affymetrix® Expression Console™ Software, while 
differential expression (DE) analysis was performed employing the Transcriptome Analysis 
Console (TAC) 3.0 Software. The One-Way between-subject ANOVA algorithm was used on 
normalized data to calculate statistical significances of pairwise comparisons. 
miRNA-gene Anticorrelation Study 
Pearson correlation coefficient was calculated on miRNA/gene pairs for miRNAs hsa-miR-130b-
5p, hsa-miR-139-5p and hsa-miR-99b-3p, and all genes with an official gene symbol reported in 
the HTA 2.0 Affymetrix gene expression analysis above.  All pairs with Pearson correlation 
coefficient < 0 and p-value < 0.05 were selected for further analyses. 
Functional Enrichment Analysis 
For each miRNA mentioned above, the set of predicted targets was intersected with the set of 
anti-correlated genes and the resulting set was used as input for a functional enrichment analysis 
by Ingenuity® Pathway Analysis (IPA®) software. Settings used included experimentally 
observed data for the human species.  
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4. RESULTS 
4.1 CD99 as predictive biomarker in Osteosarcoma 
4.1.1 Evaluation of prognostic potential of CD99 in OS samples 
CD99 was evaluated by immunohistochemistry in 100 primary samples of osteosarcoma. 
These patients were enrolled into ISG/OS-1, a multicenter randomized trial comparing efficacy 
and toxicity of two chemotherapy regimens, both based on MTX, CDP, ADM, and IFO and with 
the same cumulative doses but administered according to different schemes. The protocols had a 
different dose-intensity and different modality of use of IFO. In arm A, IFO was given only 
postoperatively and in patients with poor histologic response to primary chemotherapy with 
MTX, CDP, and ADM. In arm B, IFO was delivered in all patients and in the primary phase of 
chemotherapy. All patients enrolled in this study were affected by high grade OS of extremities, 
non-metastatic at diagnosis, younger than 40 years old.  
Median follow-up of the 100 OS patients was 113 months (range 9–167 months). Fifty-three 
patients (53%) remained continuously free of disease and 47 (47%) relapsed; sixty-seven 
patients were alive and thirty-three dead. The clinical-pathological features of the cohort and the 
correlation with event-free survival and overall-survival are summarized in the Table 1. 
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Characteristics  N.  %  EFS OVS 
Gender      
     Female  37 37 0.139 0.096 
     Male  63 63 
Age      
     < 14 years  40 40 0.214 0.147 
       14 years  60 60 
Histotype      
     Chondroblastic  10 10 0.162 0.522 
     Fibroblastic  10 10 
     Osteoblastic  68 68 
     Telangectatic 9 9 
      ND 3 3   
Location      
     Femur  47 47 0.164 0.743 
     Fibula  7 7 
     Humerus  18 18 
     Tibia  28 28 
Necrosis      
     Good  52 52 <0.001 0.002 
     Poor  47 47 
     ND 1 1 
Alkaline phosphatase      
 High 43 43 0.016 0.035 
Normal 54 57 
N.D. 3 3 
LDH     
High 25 25 0.005 0.030 
Normal 66 68 
ND 9 9 
 
Table1. Clinico-pathological features of OS cohort and association with survival 
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The patients have been stratified as negative and positive for the expression of CD99: 53 patients 
showed a positive expression for the molecule, 45 were barely negative for CD99; for 2 patients, 
data about immunostaining are not available. 
According to the tumor-suppressor role of CD99 in OS, a significant and positive association 
between CD99 expression and EFS was found (p-value= 0.036) when considering the entire 
cohort, as shown in figure 1. 
 
Figure 1. Kaplan Meier Survival Curves based on CD99 expression in OS 
The importance of CD99 as prognostic marker was confirmed by multivariate analysis (Cox’s 
regression test). Results of Cox’s regression test are summarized in Table 2. 
Variables associated with  
worse EFS in the entire cohort RR  95% CI  p-value  
NECROSIS: poor  3.401 1.486 to 7.576 0.004 
Alkaline phosphatase: high level 2.247 1.011 to 4.995 0.047 
Lattate dehydrogenase: high level 2.870 1.284 to 6.415 0.010 
CD99: negative expression 2.164 1.016 to 4.609 0.045 
 
Table 2. Multivariate analyses for EFS in the entire cohort 
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Then, the univariate analysis was conducted also in the two different arms of randomized study 
separately. When only the samples derive from the arm A were considered, CD99 lost its 
association with a better prognosis (EFS p value= 0.670, OVS p-value= 0.318). However, when 
we focused our attention on arm B, CD99 was associated with a better prognosis both in EFS 
and OVS, with p=0.001 and p=0.003 (Figure 3). 
 
Figure 3. Kaplan Meier Survival Curves based on CD99 expression for patients belonging to arm B 
Cox regression test confirmed the increased risk of relapsing and poor prognosis, as shown in the 
tables. 
 
Table 3 and 4. Multivariate analyses for EFS (3) and OVS (4) in arm B 
These associations are probably due to an enhanced sensitivity to the ifosfamide induced by 
CD99. 
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4.1.2 CD99 is implicated in the sensitivity of ifosfamide 
To test the hypothesis that CD99 mediates the sensitivity to ifosfamide, the difference of efficacy 
in OS cell was analyzed, correlating the IC50 to ifosfamide to the expression of CD99. 
First, two cell lines derived from xenografts was tested: one positive for CD99 (PDX-OS#19-
C2), the other barely negative (PDX-OS#2-C4). It was found that the cell line positive for CD99 
was more sensitive to 4-HOO IFO (the active compound of ifosfamide used for in vitro studies). 
This difference is statistically significant (Student’s t test p-value = 0.033). 
Data from CD99 expression analyses by FACS and IC50 doses for each cell lines analyzed were 
reported in table 5. 
Cell line % of positive cells Log Mean IC50 4-HOO-IFO 
PDX-OS#1-C4 26.5 6.1 12.5 ± 1.7 µg/mL 
PDX-OS#19-C2 77.8 23.3 2.8 ± 0.6 µg/mL 
 Table 5. CD99 expression analyses and IC50 doses for two cell lines stabilized from PDX 
Then, the sensitivity of OS cells with a forced expression of CD99 was tested against the four 
drugs of the clinical trial. As shown in the graphs below, expression of CD99 did not affect the 
sensitivity to doxorubicin, methotrexate and cisplatin, where there were no changes in the IC50 
doses between cells with forced expression of CD99 and the parental ones. However, IC50 for 
ifosfamide was significantly reduced in U-2/CD99wt 57 (IC50 = 7.3  2.5 g/mL, Student’s t test 
p-value < 0.001) and in U-2/CD99wt 136 (IC50=12.6  2.5g/mL, Student’s t test p-value = 
0.04) compared to parental cell line (IC50= 21.9  0.9 g/mL). Therefore, CD99 can enhance the 
sensitivity to ifosfamide, but has no effect in increasing the sensitivity to other drugs, as shown 
in figure 4. 
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Figure 4. IC50 doses for DXR, CDP, MTX, 4-HOO IFO of OS cell line stably transfected for overexpression of 
CD99; it’s represented the mean of at least three independent experiment 
To better comprehend why CD99 can promote the sensitivity to ifosfamide, cell cycle and 
apoptosis have been evaluated. After 48 hours of 10 g/mL treatment, there was an increase in 
the number of cells in S phase when CD99 was overexpressed (Figure 5). This data is consistent 
to the mechanism of action of IFO. 
 
Figure 5. Cell cycle analyses after 48 hours of treatment with two doses of 4-HOO IFO (3 and 10 µg/mL) 
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In addition, an increased proportion of apoptotic cells was observed in cells overexpressing 
CD99, especially with the treatment of 10 µg/mL 4-HOO IFO respect the parental ones in the 
same treatment condition, as shown in figure 6. 
 
Figure 6. Percentage of apoptotic cells analyzed as hypodiploid peak 
To try to explain why and how CD99 can modulate the sensitivity to ifosfamide, some 
mechanisms involved in resistance, like active uptake and reflux, were considered. Thus, the 
basal expression of MRP1, MRP4 and ABCG2 was analyzed by FACS in transfected cells. 
 MRP1 ABCG2 MRP4 
 % 
positive 
cells 
LOG 
MEAN 
% 
positive 
cells 
LOG 
MEAN 
% 
positive 
cells 
LOG 
MEAN 
U-2 OS 99.2 14.7 77.4 7.8 53.6 7.6 
U-2/pool 
empty 
98.9 19.5 36.2 3.7 85.9 12.9 
U-2/CD99wt 
57 
99.5 23.1 72.8 7.4 95.2 19 
U-2/CD99wt 
136  
88.7 16.3 62.6 9.8 94.5 16.4 
Table 6. FACS analyses of MRP1, MRP4 and ABCG2 in U2-OS and CD99 overexpressing clones 
As shown in the previous table, no differences that could explain the difference in sensitivity to 
ifosfamide were observed. 
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4.1.3 CD99 and immune infiltrates in osteosarcoma 
The results presented so far showed that the expression of CD99 can modify the sensitivity of 
osteosarcoma cells to ifosfamide. Considering the relevance of CD99 in lots of processes of 
immune system, the prognostic role of CD99 may also reflects its ability to communicate with 
immunological cells.  
For the same cohort analyzed for CD99 expression data were available in IHC for some markers 
of the immune infiltrates. Frequencies and association with prognosis are reported for each 
immunological marker evaluated in table 7. 
 EXPRESSION N % EFS OVS 
CD3 
None 10 11.0 
0.280 0.204 Focal 62 68.1 
Moderate 19 28.9 
CD8 
None 13 14.4 
0.001 0.013 Focal 59 65.6 
Moderate 18 20.0 
CD20 
None 32 69.7 
0.309 0.366 Focal 24 26.9 
Moderate 3 3.4 
CD68 
None 1 1.2 
0.042 0.097 
Focal 52 60.4 
Moderate 28 32.6 
Severe 5 5.8 
FOXP3 
None 58 66.7 
0.027 0.216 Focal 28 32.1 
Moderate 1 1.2 
PD1 
None 71 78.9 
0.487 0.633 Focal 16 17.8 
Moderate 3 3.3 
PDL1 
None 80 87.0 
0.671 0.178 
Focal 12 13.0 
Table 7. List of immune infiltrates markers evaluated in OS cohort and correlation with survival 
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As expected, the prognosis was better in term of both EFS and OVS when there was a 
prevalence of CD8+ T cells. Successively, a Spearman correlation test was performed to 
indagate correlations between the immune infiltrates markers and CD99. Results are summarized 
in table 8. 
Spearman 
Correlation 
CD8 PD1 FOXP3 CD20 CD68 PDL1 CD99 
CD3 Rho  
(p-value) 
0.875 
(<0.001) 
0.364 
(<0.001) 
0.382 
(<0.001) 
0.387 
(<0.001) 
0.387 
(<0.001) 
0.406 
(<0.001) 
0.178 
(0.093) 
CD8 Rho  
(p-value) 
 0.341 
(0.001) 
0.325 
(0.002) 
0.451 
(<0.001) 
0.416 
(<0.001) 
0.417 
(<0.001) 
0.236 
(0.026) 
PD1 Rho  
(p-value) 
  0.400 
(<0.001) 
0.240 
(0.030) 
0.470 
(<0.001) 
0.210 
(0.048) 
0.280 
(0.009) 
FOXP3 Rho  
(p-value) 
   0.217 
(0.045) 
0.335 
(0.012) 
0.223 
(0.038) 
0.151 
(0.165) 
CD20 Rho  
(p-value) 
    0.443 
(<0.001) 
0.265 
(0.012) 
0.125 
(0.245) 
CD68 Rho  
(p-value) 
     0.138 
(0.205) 
0.247 
(0.023) 
PDL1 Rho  
(p-value) 
      -0.007 
(0.946) 
Table 8. Summary of Spearman correlation between markes analyzed in the OS cohort 
All significant correlations with CD99 are weak due to the technique used for the expression 
analysis.  
Univariate analyses were conducted in some subgroups like CD8 and CD99 positive patients 
versus CD8 and CD99 negative, CD68 and CD99 positive versus CD68 and CD99 negative. 
These tests were carried out to understand if the association between those markers could 
improve the prognosis of patients and if there is any difference considering the entire cohort 
despite only arm B. The survival analysis in the whole cohort shows that patients positive for 
both CD8 and CD99 have a better prognosis in terms of EFS (p-value < 0.001) and OVS (p-
value = 0.016). Similar results were obtained regarding positive expression of CD99 and CD68 
(EFS p-value=0.023; OVS p-value= 0.033). When only the patients who received ifosfamide 
were considered, the p-value obtained enhanced the role of CD99 in the sensitivity of ifosfamide. 
As a matter of fact, the significance of the univariate analysis increases, as shown in figure 7. 
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Figure 7. Kaplan Meier Survival Curves based on CD8 and CD99 positive patients versus CD8 and CD99 negative, 
CD68 and CD99 positive versus CD68 and CD99 negative in arm B 
The simultaneous presence of CD8 and CD99 (or CD68 and CD99) predicts a better prognosis in 
the entire cohort (data not shown); the significance of these correlations is improved when the 
analyses were performed considering the B arm. These data suggest that CD99 is important for a 
greater response to ifosfamide also due to its possible role in modifying the composition of 
immune infiltration of the tumor. 
To give more strength to these correlation between CD99 and CD8 or CD68, a second 
independent cohort of OS was analyzed by qPCR. The cohort is composed of 48 patients 
affected by high grade OS of extremities, non-metastatic at diagnosis, younger than 40 years old. 
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All patients received neoadjuvant treatment. Half of these patients belongs to NED groups, the 
others to REL. Expression of several markers proper of immunological systems was analyzed 
through TaqMan™ Array Human Immune Panel. All these analyses were performed using 
GAPDH as reference gene. It was found that CD99 correlates with CD8A (Rho=0.508 p-
value=0.006) and CD68 (Rho=0.381 p-value=0.045).  
Altogether, these results indicate that the expression of CD99 correlates with CD8 and CD68 at 
both mRNA and protein level.  
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4.2 Post-transcriptional regulation of CD99 
In order to better comprehend the role of CD99 in human high-grade OS, the attention was 
focused on the expression’s regulation of CD99 mediated by miRNA. 
4.2.1 In silico study 
The first step for investigating miRNA regulation is to study the 3’ UTR of gene of interest. This 
is the most prominent part of the in silico approach of this kind of research. There are lots of 
software that can be used for prediction analyses of miRNA:mRNA interaction. Usually the 
prediction analysis is the combination of results obtained by at least four different software. In 
this case seven software were interrogated. Successively, there is the need to study the predicted 
miRNAs on miRNA database (like miRbase) especially for understanding their role (if the 
protein of interest has a tumor suppressor role, is better to choose an oncomiRNA), knowing the 
relative expression of the 2 isoforms (5p or 3p) and finally the involvement of these miRNAs in 
any disease. 
The chosen candidates for targeting CD99 are hsa-miR-23a-3p, hsa-miR-330-3p, hsa-miR-27a-
5p, hsa-miR190b. The sequence of CD99 and the seed sequence for each miRNA of interest are 
represented in figure 8. 
Figure 8. 3’UTR sequence of CD99 and predicted seed sequence for has-miR23a-3p(light blue), hsa-miR-330-3p 
(green), hsa-miR-190b (yellow), has-miR-271-5p (purple) 
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4.2.2 In vitro analysis 
The following step is included in the in vitro part and consists of validation of targeting through 
luciferase assay, by WB and qPCR in the cellular model of interest and some functional studies 
depending on the role of the protein and miRNA. 
First, the 3’UTR of CD99 were cloned into a commercial plasmid, the psi-check2 plasmid by 
Promega. This plasmid carries two luciferases, firefly and renilla. CD99-3’UTR is cloned fused 
with the 3’ extremity of renilla luciferase gene. Firefly luciferase is constituvely expressed and 
its luminescence signal is used as calibrator. The luciferase assay consists of a double transient 
transfection of HEK293 cells with the plasmid and the pre-miRNA of interest. If the identified 
miRNA does not target CD99, the luciferase is expressed and there is a luminescence signal. If 
the miRNA targets the 3’UTR there is no luminescence signal due to the miRNA-mediated 
downregulation. 
In the figure below there is a schematic representation of the test and how it works. 
Figure 9. Schematic representation of luciferase assay 
 
The data obtained with the luciferase assay are reported in figure 10. All differences in activity 
compared with a negative control were significant, except for miR-190. 
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Figure 10. Luciferase assay results 
For each miRNA that effectively decreases the luminescence, a mutagenic plasmid was created 
in which the seed sequence was deleted. For miRNA having more than one seed sequence was 
performed a site mutagenesis for each site and a plasmid containing all the mutated sequences 
together. Results are shown in figure 11. 
      
 
Figure 11. Luciferase assay data obtained with site-specific mutagenized plasmid 
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As shown, if the seed sequence was deleted, miRNA was not able to bind the 3’UTR and there 
was no change in the luminescence signal. These data proved the specificity of the binding of the 
predicted miRNAs to CD99. 
Furthermore, it was necessary to confirm the targeting in the model of interest, both through Real 
Time PCR and Western Blotting. After 48 hours of transfection with pre-miRNAs in OS cell 
line, the expression level of CD99 was evaluated both as mRNA and protein. 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. CD99 targeting confirmation by qPCR and WB 
After the treatment with the pre-miRNAs there was a decrease of the target molecule; based on 
these results miR-330-3p was chosen for further studies. 
First, miR-330-3p expression was evaluated in a panel of OS cell lines. A strong anticorrelation 
(Spearman correlation test, rho= -0.930, p-value= 0.017) was observed between the expression 
of miR-330 and CD99, corroborating the targeting. 
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Figure 13. Expression of hsa-miR-330-3p and CD99 in a panel of OS cell lines 
Data of miR-330-3p expression in OS samples were available thanks to the RNAseq experiment 
described in the following chapter. The graphs below show the expression of miR-330-3p and 
CD99 in OS samples, divided by their status: NED (no evidence of disease) and REL (relapsed). 
As expected, miR-330-3p expression was higher in patients who show more aggressive tumoral 
features, whereas CD99 was higher in patients with a better prognosis. It was possible to observe 
an anticorrelation between the expression of miRNA and target. Unfortunately, this correlation is 
not significant, probably due to the different techniques used for expression analysis and the 
small number of samples. 
 
  
Figure 14. Graphs represent expression of hsa-miR-330-p as number of reads and CD99 as relative abundance in 
two patients’ group (NED and REL) 
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4.2.3 Functional analysis 
Due to the importance of CD99 to regulate malignant phenotype in OS cell line, affecting 
migration capabilities, the goal of functional studies was to modulate CD99 expression through 
the treatment with pre-miRNA and antagomiRNA and observe the effects in terms of migration. 
In U- 2 OS cells, that have high expression of miR-330-3p and are negative for CD99, a 
treatment for 24 hours with an antagomiRNA increases the mRNA of the target gene (data not 
shown). Following the transfection, a wound healing assay was performed (Figure 15). 
 
Figure 15. in vitro migration scratch after 24h of treatment with antago-miR-330 in U-2 OS cells 
As expected, cells treated with the antagomir-330 migrate less than the untreated control, 
confirming both the targeting of CD99 and its implication in cell migration. The modulation of 
miR-330-3p is reflected on the signal pathway of CD99, including ROCK2. ROCK2 expression 
was evaluated by Western Blotting, after 24 hours of transient transfection with antago-miR-330 
in U-2OS (Figure 16). 
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Figure 16. Western Blot analysis of ROCK2 after 24h of treatment with antago-miR-330 in U-2 OS cells 
As expected, cells treated with antagomiR-330 showed a decreased expression of ROCK2. 
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4.3 Identification of a miRNA signature in OS 
The third part of the PhD program consisted in the identification of a miRNA signature able to 
discriminate patients with a better prognosis. 
4.3.1 Pilot study: small-RNA sequencing 
As a pilot study, a total of 21 samples were submitted for small RNA sequencing, through 
Illumina Platform. The samples can be divided in 3 biological groups: 7 healthy control like BM-
MSCs and human osteoblast, 7 patients with no recurrence or disease progression (NED) and 7 
patients relapsed with a local recurrence or a metastasis (REL). Patients were affected by high 
grade OS, localized at extremities and with no evidence of metastasis at diagnosis. The age at 
diagnosis was under 40 years and all patients was treated by neoadjuvant protocol. The median 
of time of recurrence for REL patients is 23 months (range 14-31 months), median of follow up 
for NED patients is 151 months (range 44-207 months). The bioinformatic analyses were 
performed to compare NED vs REL. 
The following graphs represents the expression of each miRNAs that was found as significantly 
deregulated in the two examined groups (Figure 15).  
 
 
Figure 15. Bar plot graphs represent the mean of reads for each samples groups 
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In order to verify the quantitative capabilities of the small RNA sequencing, the expression of all 
the 7 miRNAs was validated through qPCR.  
The following table summarizes the fold change data obtained by both the techniques. 
miRNA ID RNAseq linear FC qPCR linear FC 
hsa-miR-183-5p 5.23 6.46 
hsa-miR-130b-5p 2.75 1.89 
hsa-miR-99b-3p 2.14 1.81 
hsa-miR-139-5p -2.28 -2.28 
hsa-miR-195-5p -3.26 -1.26 
hsa-miR-3687 -5.14 1.17 
hsa-miR-335-3p -10.53 -10.40 
Table 9. Fold change obtained by analyses of RNAseq data and qPCR data 
Except for hsa-195-5p and hsa-miR-3687, the validation through qPCR gives similar results in 
term of fold change. 
 
4.3.2 Validation study: qPCR 
The following validation was conducted on 78 RNA samples derived from OS biopsies: 35 
patients belonging to the group of NED, 43 to the group of REL. Patients were affected by high 
grade OS of the extremities, they did not present evident metastasis at diagnosis and followed a 
neoadjuvant treatment. The median of follow up of this cohort is 95 months (range 6-310 
months).  
Quantitative expression analysis was performed using 2^- (delta Ct) method in order to compare 
the average of two groups.  
Three of seven miRNAs were validated and were significantly differentially expressed in the two 
groups: hsa-miR-99b-3p (Student’s t test p-value = 0.001), hsa-miR-130-3p (Student’s t test p-
value = 0.016), hsa-miR-139-5p (Student’s t test p-value = 0.045) (Figure 16). 
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Figure 16. Expression in the two samples group of the 3 miRNAs validated 
These three miRNAs are able to discriminate patients with a better prognosis.  
 
4.3.3 Gene expression profiling 
To better understand the functions of validated miRNAs, a gene expression profiling experiment 
was performed using HTA 2.0 Affimetrix microarrays for the same 21 samples used for RNAseq 
pilot study.  
Bioinformatic analyses were then performed. The first analysis regards differentially expressed 
genes between the two patients’ categories, NED and REL. In the meanwhile, miRNA-mRNA 
prediction analyses were performed for hsa-miR-99b-3p, hsa-miR-130b-5p and hsa-miR139-5p. 
Only predicted target genes were considered in following analysis. Anticorrelation coefficients 
were calculated for each miRNA-mRNA couple previously identified. In conclusion, gene set 
enrichment analyses were run for putative and anticorrelated target genes of miR-130b-5p and 
miR-139-5p. The following graphs summarize the results obtained by enrichment pathways 
analysis (Fig 17 and 18).  
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Each bar represents a pathway resulting enriched, red lines divided not significative pathway 
from significative one; significance is expressed as -log (p-value). 
 
Figure 17. Statistically enriched pathways of predicted target gene of miR-130-5p 
Interestingly, different immune response pathways emerged in this analysis.  
 
 Figure 17. Statistically enriched pathways of predicted target gene of miR-139-5p 
These pathways instead are linked to cell metabolism and may be implicated in drugs response. 
48 
 
5. DISCUSSION 
 
Osteosarcoma does not benefit of targeted therapies because it is characterized by high genetic 
instability and mutation in a broad spectrum of genes. Thus, the identification of a common 
pathogenetic event is difficult, but it is the key point for the development of targeted therapy. 
Osteosarcoma is treated with conventional chemotherapeutic agents, which have many short- 
and long-term side effects. Prognosis of OS patients may be improved through the validation of 
novel biomarkers, able to predict the response to a therapy regimen. In this manner, patients may 
be take advantage by more personalized therapeutic strategies, with the aim to limit side effects 
and improve the survival. A biomarker may be an indicator of a physiological state, of a 
pathological condition or of the pharmacological response to a therapeutic regimen. The perfect 
biomarker must have some peculiarities such as high sensitivity, specificity, robustness and 
predictive value. A non-invasive analysis would be advisable, thus the possibility to evaluate the 
biomarker in biological fluids, such as urine or blood, is appealing. This study evaluated the role 
of CD99 as a predictive and prognostic biomarker in osteosarcoma. Prognostic markers could 
give information about disease outcome independently from the type of treatment; predictive 
biomarker helps to identify patients who may respond to specific therapeutic regimen (Mc 
Shane, 2012). 
Even if the role of CD99 as oncosuppressor in OS is well documented, only a research group 
reported that the combination of CD99/HLAII co-expression may be a prognostic indicator in 
OS (Zhou, 2014). In our cohort, CD99 was associated to prognosis both in the entire cohort and 
in the arm of patients who received ifosfamide, but lacked its value in the subcohort of patients 
who did not receive ifosfamide. The involvement of CD99 in ifosfamide sensitivity was 
confirmed in vitro in different cell line models. First, two cell lines established from patients-
derived xenograft (PDX) were analyzed for the expression of CD99 and for the sensitivity to 4-
hydroperoxy ifosfamide (4-HOO IFO). Differences in IC50 doses between the two cell lines are 
statistically significant; in addition, a higher expression of CD99 corresponds to a greater 
sensitivity to 4-HOO IFO. This was also confirmed in OS cell lines stably which were 
transfected to achieve an overexpression of CD99. In fact, in cell lines with a forced expression 
of CD99, the IC50 dose for 4-HOO IFO was significantly lower if compared to parental cell lines. 
A lower IC50 dose matched an increased proportion of apoptotic cells, confirmed by the analysis 
of the hypodiploid peak after 48 hours of treatment. Unfortunately, few knowledges are available 
about mechanisms of sensitivity and resistance of ifosfamide in tumoral cells. These processes 
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may interest: detoxification of ifosfamide metabolites, which involves proteins like aldehyde 
dehydrogenase (ALDH), glucose-6-phosphate dehydrogenase (G6PD), glutathione (GSH) and 
glutathione S-transferase (GST); altered uptake and efflux of active metabolites resulting in 
modulating active transporters such as breast cancer resistance protein (BCRP) and multidrug 
resistance associated proteins (MRP1, MRP2, and MRP4). Also, DNA repair mechanism may be 
involved through modification in protein of mismatch repair (MMR) and base-excision repair 
(BER) complex, or modulation of level of MGMT. Finally, ifosfamide resistance is associated to 
escape from apoptotic signal resulting in deregulation of both pro-apoptotic (Bcl-2) and anti-
apoptotic (Bax) protein (Zhang, 2005). Analyses of some ABC transporters were performed 
trying to understand the differences revealed in IC50. No significant differences were noticed 
between cells overexpressing CD99 and parental ones. Therefore, data obtained from in vitro 
experiments could not totally explain the role of CD99 in increasing sensitivity to ifosfamide in 
OS. It is plausible an involvement of tumoral microenvironment, in particular of immune 
infiltrate, in modulating OS sensitivity to this drug.  
The involvement of different immunological cell subsets in tumor development and progression 
and their emerging role in the most effective standard or targeted therapeutic treatments for 
several tumor histotypes, suggests that understanding composition, function and sensitivity of 
immune infiltrate may represent a potentially appealing therapeutic option. Unfortunately, the 
data available for immune infiltrate in OS and its role are still limited. Presence of CD8+ T cells 
and tumor associated CD68+ macrophages (TAM) is correlated to a better prognosis in the 
cohort analyzed. Two independent studies confirmed these evidences. A study conducted on 124 
OS patients, treated with zoledronic acid, demonstrated the prognostic value of CD8+ T cells 
(Gomez-Broucher, 2017). As demonstrated by Buddingh, the number of TAM was associated to 
a better outcome. Also, in a multivariate model, a high number of TAM was associated with the 
response to chemotherapy, suggesting a role of immune infiltrate in sensitivity to drugs 
(Buddingh, 2011). The involvement of CD99 in immunological processes leads to study the 
possible connection between expression of CD99 and markers of immune infiltrates of the 
tumor. CD99 positive tumors are associated to infiltration by CD8+ and CD68+ immune cells, 
suggesting a role of CD99 in recruitment of immune cells to tumoral site. Survival analysis 
demonstrated that the simultaneous presence of CD8 and CD99 (or CD68 and CD99) predicted a 
better prognosis in the entire cohort; the significance of these analyses was improved when only 
arm B was considered. These data suggest that CD99 and tumor microenvironment, especially 
the immune infiltrate, are important for a greater response to ifosfamide. Oxazaphoshorines 
show immunomodulatory effects, probably due to a bystander effect in the modulation of tumor 
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microenvironment. This class of chemotherapeutic agents can enhance the antitumor activity of 
immune cells through several mechanisms, such as homeostatic proliferation, induction of 
expression of cytokines and removing of suppressor T cells (Proietti, 1997; Binotto, 2003; 
Bracci, 2007). Homeostatic proliferation leads the maintenance of T cell population by both de 
novo T cell production in thymus and by the long-term survival of memory T cells (Surh, 2000).  
As known, CD99 is highly expressed in memory B and T cells (Park, 1999; Yoon, 2003). It is 
possible to speculate about a role of CD99 in the recruitment of memory T cells at the tumor site, 
through heterodimerization between CD99 expressed on tumoral cells and on T cells. 
Additionally, to corroborate the importance of CD99 in response to ifosfamide, in Gougelet et al. 
a panel of 6 miRNAs were identified as essential for the response to this drug and some of these, 
such as miR-30c and let-7, can target CD99 (Gougelet, 2011). 
So, CD99 acts in osteosarcoma as oncosuppressor affecting migration and cell differentiation 
and its role as a predictive factor has been demonstrated. It is important to have a better 
knowledge of the regulation of this protein in osteosarcoma. Less is known about transcriptional 
and post transcriptional regulation of CD99. In fact, only miR-30a-5p is validated for targeting 
CD99 in Ewing Sarcoma (Franzetti, 2013). In this study, miRNA-mediated downregulation was 
investigated with the aim to validate new miRNAs able to target CD99 in OS cells. In silico 
predictions led to the identification of several miRNAs, but the choice of miR-23a-5p, miR-27a-
5p, miR-190 and miR-330-3p was due to their thermodynamic aspect, type of seed sequence, and 
presence of multiple sites in the 3’UTR of CD99. The targeting was confirmed for miR-23a-5p, 
miR-27a-5p and miR-330-3p through luciferase assays in recipient cells and by qPCR and 
Western Blotting in the model of interest. Functional studies were conducted only for miR-330-
3p because of its capacity of giving a stronger silencing of CD99 in OS cells. Moreover, basal 
expression of this miRNA anticorrelated with CD99 expression in a panel of OS cell lines. 
Functional studies showed that miR-330 affected migration and modulated expression of 
ROCK2. miR-330-3p has therefore an oncogenic role in osteosarcoma. Evidences about the role 
of miR-330-3p are contradictory. Like other miRNAs, it may act both as oncomiR and 
oncosuppressor miRNA, depending on cell types. In Chronic Fatigue Syndrome, upregulation of 
miR-330 induces a decrease of MMP9 protein level, confirming the role of this microRNA in 
cellular migration (Petty, 2016). Also in Non-Small Cell Lung Cancer (NSCLC), miR-330 has 
oncogenic role, confirmed by a higher expression in tumoral samples comparing to normal 
samples. miR-330-3p induces the downregulation of early growth response 2 (EGR2), leading in 
cell proliferation in vitro and cell cycle progression in NSCLC (Liu, 2015). Moreover, in 
NSCLC miR-330 expression is associated to tumor invasion and brain metastasis growth through 
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the activation of MAPK/ERK pathway and directly targeting GRIA3 (Wei, 2017). The same 
effects observed in NSCLC about the downregulation of EGR2 were confirmed in osteosarcoma 
model by Zhuo and colleagues (Zhou, 2015). In glioblastoma, miR-330-3p regulate cell 
migration and invasion ability through downregulation of SH3GL leading in activation of 
PI3K/Akt and ERK modulation. In breast cancer, miR-330-3p promotes metastases development 
through targeting of CCBE1 (Mesci, 2017). Also in hepatocellular carcinoma (HCC), a high 
expression of miR-330 correlates with poor prognosis. miR-330 promotes cell growth and 
invasion targeting ING4, a gene involved in modulation of gene transcription via interaction with 
histone acetyltransferase and histone deacetyltransferase (Hu, 2016). Finally, in esophageal 
cancer miR-330 interacts with Programmed Cell Death 4 (PDCD4). The main effects of this 
interaction are the increase of cell growth, cell migration, invasion and inhibition of cisplatin-
induced apoptosis (Meng, 2015). In our data set deriving from a pilot study on small RNA 
sequencing, miR-330 is expressed at higher levels in relapsed patients in comparison to those 
who remained continuously disease-free. Unfortunately this difference is not significant, 
probably due to the small cohort analyzed. Taken together, these evidences may corroborate a 
tumor-inducing role of miR-330 in OS. 
The pilot study on Small RNA sequencing consisted in analyzing 3 biological groups composed 
by 7 RNA samples from healthy controls (bone-marrow mesenchymal stem cells and 
osteoblasts), 7 extracted from biopsies of NED (no evidence of disease) patients and 7 from REL 
(relapsed) patients. The goal was to identify miRNAs and others small RNAs able to 
discriminate these subgroups, in particular NED versus REL. Several studies on miRNA 
signature are available in literature. The first OS signature was identified by Jones, that analyzed 
a total of 18 OS samples using microarray-based techniques. They identified 34 miRNAs 
deregulated in OS specimens in comparison to normal tissue, providing a miRNome associated 
to OS pathogenesis (Jones, 2012). A second miRNA signature was discovered in a cohort of 27 
patients of Mexican-American ethnicity, affected by high grade OS of extremities. Expression 
analyses of 754 miRNAs were performed through High-throughput RT-qPCR. They found 42 
miRNAs that were associated to survival in OS (Sanchez-Diaz, 2014). The last miRNA signature 
discovered consists in 29 miRNAs. The discovery set of 23 patients were analyzed for the 
expression of 752 miRNA through High-throughput RT-qPCR. These miRNAs were analyzed 
on 101 samples. This is the largest cohort published for this type of studies (Andersen, 2017). In 
our data set, for the first time small RNA sequencing was performed with the aim to discover a 
miRNA signature. It is also possible to identify other differentially expressed small RNAs in our 
cohort, such as piRNA, snoRNA, tsRNA. Bioinformatic analyses revealed a list of 7 
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significantly deregulated miRNAs in the two patients’ groups. The validation was then 
conducted by qPCR in a larger cohort composed by 35 NED and 43 REL patients. Three of 
seven miRNAs were validated and were significantly differentially expressed between the two 
groups: hsa-miR-99b-3p (Student’s t test p-value = 0.001), hsa-miR-130-3p (Student’s t test p-
value = 0.016), and hsa-miR-139-5p (Student’s t test p-value = 0.045). miR-99b-3p and miR-
130b-3p were upregulated in REL, suggesting an oncogenic role; conversely, miR-139-5p was 
downregulated in REL, in line with a possible oncosuppressor function. The better-understood 
miRNA is hsa-miR139-5p, while less or nothing is known for the other two.  
A revision of literature showed that miR-139-5p has oncosuppressive features in several tumor 
types, like hepatocellular carcinoma, breast cancer, esophageal cancer, bladder cancer, colon 
rectal cancer, acute myeloid leukemia (Wong, 2011; Liu, 2013; Song, 2014; Xu, 2016; Luo, 
2017; Krowiorz, 2016). miR-139-5p exerts its tumor suppressive role at different levels, such as 
cell growth and apoptosis, cellular migration, and invasion. In NSCLC miR-139-5p suppresses 
cell growth, metastasis formation and induction of apoptosis through direct targeting of IGF1R, 
CCDN1, KIP27, MMP7, MMP9 and c-MET (Xu 2015; Sun, 2015). Two independent studies 
demonstrated that miR-139-5p is less expressed in colonrectal cancer in comparison to the 
normal counterpart, moreover low expression of this miRNA is associated to poor prognosis. 
miR-139-5p inhibits cell migration and invasion through targeting Notch1 (Song, 2014). miR-
139-5p is also involved in sensitivity to oxaliplatin and fluorouracil in multidrug resistant cell 
lines of CRC. Low expression of the miRNA makes cells more resistant to chemotherapeutic 
agents and this effect may be partially reverted through overexpression of Notch1. These data 
confirm the importance of miR-139-5p Notch1 axis in tumorigenesis and chemoresistance in 
CRC (Xu, 2016). miR-139-5p can modulate invasion and migration abilities in vitro thanks to 
direct targeting of ROCK2. miR-139-5p ROCK2 targeting has been confirmed in three different 
tumoral model, such as hepatocellular carcinoma, ovarian cancer and colorectal cancer (Wong, 
2011; Wang, 2017; Shen, 2014). Few studies are available for miR-99b-3p and miR-130b-5p. 
The role of miR-99b-3p was studied in oral squamous cell carcinoma (OSCC) in which it has 
oncosuppressive characteristics thanks to the inhibition of glycogen synthase kinase-3β 
(GSK3β). Indeed, downregulation of GSK3β leads to the inhibition of OSCC cell proliferation 
and suppression of p65 (RelA) and G1 regulators (cyclin D1, CDK4 and CDK6) in vitro (He, 
2015). miR-130b-5p belongs to a 25 miRNAs signature of triple negative breast cancer; miR-
130b-5p is more expressed in tumor samples in comparison to normal adjacent tissue and exerts 
its oncogenic role through direct targeting CCNG2. Inhibition of CCNG2 induces cell 
proliferation (Chang, 2015). In human epithelial ovarian cancer (EOC), miR-130b-5p is 
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overexpressed in tumoral tissues in respect to normal ones (Wang, 2014). The data available 
about miR-99b-3p and miR-130b-5p contrast with the possible role of these molecules in OS. 
For understanding the biological role of these miRNAs in osteosarcoma a gene expression 
profiling experiment was conducted on the same 21 samples. The analyses were conducted in the 
two patients’ groups: differentially expressed genes between NED and REL were compared to 
the lists of potential targets for each miRNA validated. Finally, enrichment pathway analyses 
were performed for a greater comprehension of the biological function of these miRNAs in OS 
models. miR-130b-5p seems to be involved in the interaction with immunological processes. In 
fact, 12 of 31 significantly enriched pathways involved immune cell communication or pathways 
proper of immune system, like communication between innate and adaptive immune cells, NF-
kB signaling, and IL-10 pathway. In particular, IL-33 seems to be an important target of miR-
130b and it is also found as part of the 9 pathways emerged by enrichment analyses.  IL-33 
belongs to the IL-1 family and its cognate receptor is ST2 (suppression of tumorigenicity 2). IL-
33 has a key role in tissue homeostasis and responses to environmental stresses; it acts as an 
alarmin secreted by damaged and necrotic cells. It is constitutively expressed in almost all cell 
and tissue types (Liew, 2016). Loss of IL-33 is associated to metastases development in 
carcinomas through a mechanism of immune surveillance escape (Saranchova, 2016). Moreover, 
low expression of IL-33 is associated to a poor prognosis in OS (Koster, under review). miR-
139-5p seems to be involved in cellular metabolism, as demonstrated by enriched pathways such 
as glycolysis, gluconeogenesis and mTOR signaling. Moreover, pathways like salvage pathway 
of pyrimidine ribonucleotides and pyridoxal 5'-phosphate are enriched, suggesting a role of miR-
139-5p in resistance to classical chemotherapeutic agent. 
In conclusion, the predictive and prognostic role of CD99 in OS has been reported. In clinical 
samples, CD99 acts as a predictive biomarker for ifosfamide response. CD99 is associated with 
an increased sensitivity in OS cell lines, corresponding to a greater apoptosis rate. CD99 tumoral 
expression correlates to an enrichment in CD8+ and CD68+ cells in OS samples. Taken together 
these data confirm a role of CD99 in ifosfamide sensitivity in osteosarcoma, thus CD99 is able to 
increase both the cytotoxic and the immunomodulatory effects of ifosfamide, making 
osteosarcoma cells more sensitive. The study regarding post-transcriptional regulation of CD99 
identifies hsa-miR-330-3p as a modulator of CD99 expression. Moreover, miR-330-3p affects 
downstream effector of CD99, like ROCK2, leading to a modulation of migration capabilities. 
Finally, a 3-miRNA signature (hsa-miR-99b-3p, hsa-miR-130b-5p and hsa-miR-139-5p), 
identified by small RNA sequencing, discriminates patients who remained disease-free from 
those who relapsed. Enrichment pathway analyses showed the involvement of these miRNAs in 
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immunological processes and cellular metabolism, underlining the importance of these 
mechanisms in the pathogenesis and response to therapy in OS. 
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